Show simple item record

dc.contributor.authorAndersen, Kari-Mette
dc.contributor.authorKristoffersen, Anne Karin
dc.contributor.authorIngebretsen, André
dc.contributor.authorVikholt, Katharina Johnsen
dc.contributor.authorOlsen, Ingar
dc.contributor.authorEnersen, Morten
dc.contributor.authorGaustad, Peter
dc.date.accessioned2016-08-29T10:46:01Z
dc.date.available2016-08-29T10:46:01Z
dc.date.issued2016-02-08
dc.description.abstractBACKGROUND: Increasing numbers of immunocompromised patients have resulted in greater incidence of invasive fungal infections with high mortality. Candida albicans infections dominate, but during the last decade, Candida glabrata has become the second highest cause of candidemia in the United States and Northern Europe. Reliable and early diagnosis, together with appropriate choice of antifungal treatment, is needed to combat these challenging infections. OBJECTIVES: To confirm the identity of 183 Candida glabrata isolates from different human body sites using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and VITEK®2, and to analyze isolate protein profiles and antifungal susceptibility. The minimum inhibitory concentration (MIC) of seven antifungal drugs was determined for the isolates to elucidate susceptibility. DESIGN: A total of 183 C. glabrata isolates obtained between 2002 and 2012 from Norwegian health-care units were analyzed. For species verification and differentiation, biochemical characterization (VITEK®2) and mass spectrometry (MALDI–TOF) were used. MIC determination for seven antifungal drugs was undertaken using E-tests®. RESULTS: Using VITEK®2, 92.9% of isolates were identified as C. glabrata, while all isolates (100%) were identified as C. glabrata using MALDI-TOF. Variation in protein spectra occurred for all identified C. glabrata isolates. The majority of isolates had low MICs to amphotericin B (≤1 mg/L for 99.5%) and anidulafungin (≤0.06 mg/L for 98.9%). For fluconazole, 18% of isolates had MICs >32 mg/L and 82% had MICs in the range ≥0.016 mg/L to ≤32 mg/L. CONCLUSIONS: Protein profiles and antifungal susceptibility characteristics of the C. glabrata isolates were diverse. Clustering of protein profiles indicated that many azole resistant isolates were closely related. In most cases, isolates had highest susceptibility to amphotericin B and anidulafungin. The results confirmed previous observations of high MICs to fluconazole and flucytosine. MALDI-TOF was more definitive than VITEK®2 for C. glabrata identification.en_US
dc.description.sponsorshipThis study was funded by the University of Oslo (Faculty of Dentistry and Faculty of Medicine), the University of Tromsø (Institute of Clinical Odontology) and a grant for scientific research from the NORM-VET program in 2013. I. O. was funded through a grant from the European Commission (FP7-HEALTH-306029 ‘TRIGGER’).en_US
dc.descriptionPublisher's version, source: <a href=http://dx.doi.org/10.3402/jom.v8.29849>http://dx.doi.org/10.3402/jom.v8.29849</a>.en_US
dc.identifier.citationJournal of Oral Microbiology 2016, 8: 29849en_US
dc.identifier.cristinIDFRIDAID 1304271
dc.identifier.doi10.3402/jom.v8.29849
dc.identifier.issn2000-2297
dc.identifier.urihttps://hdl.handle.net/10037/9576
dc.identifier.urnURN:NBN:no-uit_munin_9129
dc.language.isoengen_US
dc.publisherCo-Action Publishingen_US
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830::Andre kliniske odontologiske fag: 849en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715en_US
dc.subjectC. glabrataen_US
dc.subjectidentificationen_US
dc.subjectbiochemicalen_US
dc.subjectMALDI-TOFen_US
dc.subjectMICsen_US
dc.titleDiversity and anti-fungal susceptibility of Norwegian Candida glabrata clinical isolatesen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record